Thanks to our great Clients, Partners, Colleagues, Family and Friends, we’re celebrating the completion of our first year in business.
Thanks for helping to make DelveInsight a success!!
DelveInsight Blog
Related Article
Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval
FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...
Find More
Business Consultants: An Intense Drive to Work Excellence
Consultancy comes from the Latin consultare, which means "to discuss." Usually, a professional providing expert advice in a specific area can be called a consultant, a group of individuals - consultancy. Business Consultancy requires dealing with a broad range of activities, and every firm or individual involved...
Find More
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19
Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555. LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...
Find MoreEditor's Pick
Newsletter/Whitepaper
-Agonist.png "Toll-like Receptors Agonist")
Recent Article
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.